Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q4 FY23 Earnings Presentation
25 slides from Themis Medicare's earnings presentation, May 15, 2023
Slide 1: Exchange filing cover letter: Investor Presentation
TML: CS: BSE/NSE CORR: 2023-24 15th May, 2023 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, Bandra – East, Mumbai- 400 051 Dear Sir/Madam, Sub: Subject: Investor Presentat
Slide 2: Themis Medicare Ltd. Investor Presentation Q4 & FY23
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Investor Presentation Q4 & FY23
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Recent Developments
Recent Developments • Received DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing. It will be marketed under brand name REMITHEM®, rapid-acting narcotic analgesic that fulfills long-awaited need in Indian market • Received no objection from DCGI for manufactur
Slide 7: Consolidated Quarterly Financial Highlights – Q4 FY22-23
Consolidated Quarterly Financial Highlights – Q4 FY22-23 Particulars (Rs. Cr.) Q4 FY22-23 Q4 FY21-22 Y-o-Y (%) Q3 FY22-23 Net Revenue 80.10 79.80 0.39% 88.78 Cost of Material Consumed 30.32 27.12 29.77 Purchase of SIT 10.58 5.88 6.26 Changes in Inventory (13.10) (6.25) (2.60) Employee Expenses 17.72
Slide 8: Consolidated Financial Highlights
Consolidated Financial Highlights 262.6 Revenue (Rs. Cr.)* Revenue (Rs. Cr.) 394.6 354.3 API Formulation 220.0 230.7 150.3 201.6 129.2 136.0 132.0 183.8 124.0 80.5 65.6 54.6 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 EBITDA (Rs. Cr.)** / Margin (%) PAT (Rs. Cr.)
Slide 9: Annual Consolidated Financial Highlights – FY22-23
Annual Consolidated Financial Highlights – FY22-23 Particulars (Rs. Cr.) FY22-23 FY21-22 Y-o-Y (%) Net Revenue 354.32 394.61 (10.21%) Cost of Material Consumed 96.04 113.63 Purchase of SIT 30.12 31.45 Changes in Inventory (7.79) 3.06 Employee Expenses 66.15 51.97 Other Expenses 102.36 98.87 Total Ex
Slide 10: Balance Sheet Ratios
Balance Sheet Ratios Working Capital Days Debt to Equity* 231 0.67 0.67 219 167 179 0.46 120 0.27 0.27 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 RoCE** RoE*** 25.34% 25.23% 14.69% 15.88% 16.15% 16.64% 10.93% -1.27% -6.84% 13.50% FY18-19 FY19-20 FY20-21 FY21-22 F
Slide 11: Consolidated Balance Sheet as on 31st Mar'23
Consolidated Balance Sheet as on 31st Mar’23 As on 31st As on 31st As on 31st As on 31st Rs. Cr. Rs. Cr. Mar’23 Mar’22 Mar’23 Mar’22 Shareholders Funds 339.44 287.49 Non Current Assets 249.42 213.62 Share Capital 9.20 9.20 Plant, Property & Equipment 160.97 141.79 Other Equity 330.24 278.29 Capital
Slide 12: Company Overview
Company Overview
Slide 13: Snapshot of Company
Snapshot of Company 1969 Strategic focus 3 4,000+ Themis Chemicals To become Leader in Hospital State of art Nationwide stockists' established Business in India manufacturing facilities network in India – 1 Formulations and 2 APIs 44+ Rs. 1,073 Cr Rs. 57 Cr Countries that we Export Market Cap PAT (A
Slide 14: Business Segments
Business Segments Formulations APIs 1 Formulations 2 Synthetic API’s 3 Facilities Haridwar Vapi Hyderabad Contributes 64% of Total Revenue (FY22- 23) Contributes 36% of Total Revenue (FY22-23) Hospital business Hospital Business Other Businesses Centre of growth of Total Revenue of Total Revenue 33%
Slide 15: Strong Business Model
Strong Business Model Businesswise Revenue –FY22-23 Others Hospital 20% 33% Product API Trade Development (R&D) 03 36% 11% 01 n 02 Hospital Business n Businesswise Revenue – FY21-22* API Business Critical Care Division Others Narcotics API Legacy Business 15% Hospital Instuition Business A
Slide 16: Hospital Business – Major Growth Driver
n Hospital Business – Major Growth Diver Hospital Portfolio can Include… Anti Infectives Sterile Injectibles Surgical Products Anesthesia Unique / Differentiated Products New Opportunities… Product Portfolio Current TML Portfolio To be Included Anesthesia Intensive Care Medical Devices Nutriti
Slide 17: TML Presence across Hospital Business
n TML Presence across Hospital Business Critical Care Division Institutions Intensive Care (CCD) and Narcotics 11 years old West and South part of India Proprietary TML Good presence in hospital to be fully operational from business Formulations Key Molecules December 2022 – will extend St
Slide 18: API Segment – Overview & Strategy
API Segment – Overview & Strategy Major Existing Products Simvastatin - Largest selling API product for Company Out of Total Production – API (FY22-23) Fumagilline - Niche product Domestic 2% Ketamine - DMF filings are planned in semi regulated markets Exports 98% Business Strategy for New Pro
Slide 19: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Haridwar Hyderabad Vapi Particulars Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Injections Artemether, Ferracrylum, Lumefantrine,
Slide 20: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations Total Manpower 54 12 13.64 R&D 29 (Incl. 5 PhD) 6 (Incl. 1 PhD) 9.51 8.50 Analytical Lab 15 6 Development 5.28 4.59 Groups 5 3 3.43 Product in a year with 5–8 20-24 documentation FY17-18 FY18
Slide 21: Way Ahead
Way Ahead
Slide 22: Key Growth Triggers
Key Growth Triggers DISTRIBUTION NETWORK & PRODUCT PIPELINE RELATIONSHIPS Strong relationships with both First to Launch opportunities private and Govt. hospitals & Complex generic Pipeline in development institutions Generics – target to launch 10 – 12 Deep distribution network to product
Slide 23: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Anesthesia Market Highly Fragmented unlike West where 3-4 players control 90% market share High Entry Barriers Large Product Portfolio needed to service this segment Takes t
Slide 24: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 25: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac